Mergers & Acquisitions Mergers & Acquisitions

Hypera-Sanofi deal faces more scrutiny in Brazil after being declared 'complex'

By Ana Paula Candil
  • 20 Dec 2021 16:18
  • 20 Dec 2021 16:18
Hypera's planned buyout of 12 medicine brands from Sanofi Medley Farmacêutica has been declared "complex" by the Brazilian competition authority and will require an in-depth analysis because of what the agency deemed high concentration levels in certain markets.
They include stimulant laxatives and prescription nasal decongestants.

"During the market test,

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Ana Paula Candil

Senior Correspondent, Latin America

Ana Paula joined MLex in Brazil in 2014 writing about antitrust investigations and merger reviews. Prior to that, she worked for several trade publications and in TV. She lived in Washington DC, where she worked for Al Jazeera English in 2010. She studied journalism and holds a postgraduate diploma in International Business Management from the George Brown College in Toronto and a Master of Business Administration diploma in government relations from Fundação Getúlio Vargas (FGV).

Discover MLex

Stay on top of global regulatory developments

Latest News